BLAINJECTIONSOLUTIONPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
Priority Review
EVKEEZA (evinacumab) by Regeneron is angiopoietin-like 3 inhibitors [moa]. Approved for angiopoietin-like 3 inhibitor [epc]. First approved in 2021.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVKEEZA (evinacumab) is a monoclonal antibody that inhibits angiopoietin-like 3 (ANGPTL3), a regulator of triglyceride and LDL cholesterol metabolism. It is indicated for patients with severe hypertriglyceridemia or homozygous familial hypercholesterolemia who have inadequate lipid control on standard therapies. The drug works by blocking ANGPTL3 to reduce circulating triglycerides and cholesterol levels.
$7MPart D
PeakProduct is at peak lifecycle with modest Part D utilization (163 claims in 2023), indicating a niche market; commercial team is likely stabilized with focus on market penetration and indication expansion.
Mechanism of Action
Angiopoietin-like 3 Inhibitors
Pharmacologic Class:
Angiopoietin-like 3 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Started Mar 2026
52 enrolled
Homozygous Familial Hypercholesterolemia (HoFH)Coronary Computed Tomography Angiography
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia
Started Feb 2023
10 enrolled
Homozygous Familial Hypercholesterolemia
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
Started Jul 2021
21 enrolled
Hypertriglyceridemia
Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
Started Jun 2020
20 enrolled
Homozygous Familial Hypercholesterolemia
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Started Jun 2018
52 enrolled
Severe Hypertriglyceridemia (sHTG)
Worked on EVKEEZA at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.